Surgical advances in bladder cancer: At what cost?

Urologic Clinics of North America

Volumn 42, Issue 2, 2015, Pages 235-252

  Johnson, David C ^a   Greene, Peter S ^a   Nielsen, Matthew E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Alvimopan; Bladder cancer; Blue light cystoscopy; Costs; Quality of life; Robotic cystectomy

Indexed keywords

ALVIMOPAN; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; GASTROINTESTINAL AGENT; PIPERIDINE DERIVATIVE;

ARTICLE; BLADDER CANCER; BLEEDING; BLOOD TRANSFUSION; BLUE LIGHT CYSTOSCOPY; CARCINOMA IN SITU; CLINICAL EFFECTIVENESS; CYSTECTOMY; CYSTOSCOPY; HEALTH CARE COST; HUMAN; LENGTH OF STAY; META ANALYSIS (TOPIC); PATIENT CARE; PERIOPERATIVE PERIOD; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; ROBOT ASSISTED SURGERY; SAFETY; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW (TOPIC); ADVERSE EFFECTS; COST BENEFIT ANALYSIS; ECONOMICS; ILEUS; PATHOLOGY; ROBOTIC SURGICAL PROCEDURE; URINARY BLADDER NEOPLASMS;

COST-BENEFIT ANALYSIS; CYSTECTOMY; CYSTOSCOPY; GASTROINTESTINAL AGENTS; HEALTH CARE COSTS; HUMANS; ILEUS; LENGTH OF STAY; PIPERIDINES; ROBOTIC SURGICAL PROCEDURES; URINARY BLADDER NEOPLASMS;

EID: 84955373793     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2015.01.005     Document Type: Review

References (99)

1. Riley GF, Potosky AL, Lubitz JD, et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995; 33(8):828-41.
2. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21(18):1315-30.
3. Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics 2014;32(11): 1093-104.
4. American Urological Association: Guideline for the management of nonmuscle invasive bladder cancer (stages ta, T1, and tis): 2007 update. Updated 2007. Available at: www.auanet.org. Accessed September 25, 2014.
5. Clark PE, Agarwal N, Biagioli MC, et al. Bladder cancer. J Natl Compr Canc Netw 2013;11(4):446-75.
6. Babjuk M, Burger M, Zigeuner R, et al.EAUguidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64(4):639-53.
7. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55(1):164-74.
8. Svatek RS, Fisher MB, Matin SF, et al. Risk factor analysis in a contemporary cystectomy cohort using standardized reporting methodology and adverse event criteria. J Urol 2010;183(3):929-34.
9. Johnson DC, Nielsen ME, Matthews J, et al. Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. BJU Int 2014;114(2):221-8.
10. Hu M, Jacobs BL, Montgomery JS, et al. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer 2014;120(9):1409-16.
11. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006;68(3):549-53.
12. Yabroff KR, Bradley CJ, Mariotto AB, et al. Estimates and projections of value of life lost from cancer deaths in the united states. J Natl Cancer Inst 2008;100(24):1755-62.
13. Gore JL, Gilbert SM. Improving bladder cancer patient care: a pharmacoeconomic perspective. Expert Rev Anticancer Ther 2013;13(6):661-8.
14. Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 2009;27(3):295-300.
15. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466-75 [discussion: 475-7].
16. Divrik RT, Sahin AF, Yildirim U, et al. Impact of routine second transurethral resection on the longterm outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010;58(2):185-90.
17. Karaolides T, Skolarikos A, Bourdoumis A, et al. Hexaminolevulinate-induced fluorescence versus white light during transurethral resection of noninvasive bladder tumor: does it reduce recurrences? Urology 2012;80(2):354-9.
18. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a metaanalysis of detection and recurrence based on raw data. Eur Urol 2013;64(5):846-54.
19. Witjes JA, Babjuk M, Gontero P, et al. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations. Eur Urol 2014;66 [pii: S0302-2838(14)00611-3].
20. Oude Elferink P, Witjes JA. Blue-light cystoscopy in the evaluation of non-muscle-invasive bladder cancer. Ther Adv Urol 2014;6(1):25-33.
21. Stenzl A, Burger M, Fradet Y, et al. Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol 2010;184(5):1907-13.
22. Burger M, Stief CG, Zaak D, et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology 2009;74(6): 1282-6.
23. Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003;170(2 Pt 1):428-32.
24. Yuan H, Qiu J, Liu L, et al. Therapeutic outcome of fluorescence cystoscopy guided transurethral resection in patients with non-muscle invasive bladder cancer: a meta-analysis of randomized controlled trials. PLoS One 2013;8(9):e74142.
25. Rink M, Babjuk M, Catto JW, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with nonmuscle-invasive bladder cancer: a critical review of the current literature. Eur Urol 2013;64(4):624-38.
26. Witjes JA, Gomella LG, Stenzl A, et al. Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data. Urology 2014;84(1):122-6.
27. Cysview (hexaminolevulinate hydrochloride), for intravesical solution-highlights of prescribing information. Updated 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022555s000lbl.pdf. Accessed October 3, 2014.
28. Bunce C, Ayres BE, Griffiths TR, et al. The role of hexylaminolaevulinate in the diagnosis and followup of non-muscle-invasive bladder cancer. BJU Int 2010;105(Suppl 2):2-7.
29. Malmstrom PU, Grabe M, Haug ES, et al. Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance. Scand J Urol Nephrol 2012;46(2):108-16.
30. Daneshmand S, Schuckman AK, Bochner BH, et al. Hexaminolevulinate blue-light cystoscopy in nonmuscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol 2014;11(10):589-96.
31. Dindyal S, Nitkunan T, Bunce CJ. The economic benefit of photodynamic diagnosis in non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther 2008;5(2):153-8.
32. Burger M, Zaak D, Stief CG, et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germanybased cost analysis. Eur Urol 2007;52(1):142-7.
33. Otto W, Burger M, Fritsche HM, et al. Photodynamic diagnosis for superficial bladder cancer: do all riskgroups profit equally from oncological and economic long-term results? Clin Med Oncol 2009;3:53-8.
34. Malmstrom PU, Hedelin H, Thomas YK, et al. Fluorescence-guided transurethral resection of bladder cancer using hexaminolevulinate: analysis of health economic impact in Sweden. Scand J Urol Nephrol 2009;43(3):192-8.
35. Garfield SS, Gavaghan MB, Armstrong SO, et al. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol 2013;20(2):6682-9.
36. Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188(1):58-62.
37. Marteau F, Kornowski A, Bennison C, et al. Cost-effectiveness of the optical imaging agent hexaminolevulinate for patients undergoing initial transurethral resection of non-muscle invasive bladder cancer tumours. Eur Urol Suppl 2013;12(125) [abstract: 01].
38. O'Brien T, Ray E, Chatterton K, et al. Prospective randomized trial of hexylaminolevulinate photodynamicassisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer. BJU Int 2013;112(8):1096-104.
39. Geavlete B, Multescu R, Georgescu D, et al. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with nonmuscle-invasive bladder cancer (NMIBC)? BJU Int 2012;109(4):549-56.
40. Menon M, Hemal AK, Tewari A, et al. Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int 2003;92(3):232-6.
41. Leow JJ, Reese SW, Jiang W, et al. Propensitymatched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the united states. Eur Urol 2014;66(3):569-76.
42. Monn MF, Cary KC, Kaimakliotis HZ, et al. National trends in the utilization of robotic-assisted radical cystectomy: an analysis using the nationwide inpatient sample. Urol Oncol 2014;32(6):785-90.
43. Li K, Lin T, Fan X, et al. Systematic review and metaanalysis of comparative studies reporting early outcomes after robot-assisted radical cystectomy versus open radical cystectomy. Cancer Treat Rev 2013;39(6):551-60.
44. Tang K, Xia D, Li H, et al. Robotic vs open radical cystectomy in bladder cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2014;40(11): 1399-411.
45. Ishii H, Rai BP, Stolzenburg JU, et al. Robotic or open radical cystectomy, which is safer? A systematic review and meta-analysis of comparative studies. J Endourol 2014;28(10):1215-23.
46. Nix J, Smith A, Kurpad R, et al. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 2010;57(2): 196-201.
47. Kader AK, Richards KA, Krane LS, et al. Robot-assisted laparoscopic vs open radical cystectomy: comparison of complications and perioperative oncological outcomes in 200 patients. BJU Int 2013;112(4):E290-4.
48. Niegisch G, Albers P, Rabenalt R. Perioperative complications and oncological safety of robotassisted (RARC) vs open radical cystectomy (ORC). Urol Oncol 2014;32(7):966-74.
49. Musch M, Janowski M, Steves A, et al. Comparison of early postoperative morbidity after robot-assisted and open radical cystectomy: results of a prospective observational study. BJU Int 2014;113(3):458-67.
50. Ahdoot M, Almario L, Araya H, et al. Oncologic outcomes between open and robotic-assisted radical cystectomy: a propensity score matched analysis. World J Urol 2014;32(6):1441-6.
51. Merseburger AS, Herrmann TR, Shariat SF, et al. EAU guidelines on robotic and single-site surgery in urology. Eur Urol 2013;64(2):277-91.
52. Parekh DJ, Messer J, Fitzgerald J, et al. Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy. J Urol 2013; 189(2):474-9.
53. Bochner BH, Sjoberg DD, Laudone VP, Memorial Sloan Kettering Cancer Center Bladder Cancer Surgical Trials Group. A randomized trial of robotassisted laparoscopic radical cystectomy. N Engl J Med 2014;371(4):389-90.
54. Keren Paz GE, Laudone VP, Bochner BH. Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery? Curr Opin Urol 2013;23(5):449-55.
55. Khan MS, Elhage O, Challacombe B, et al. Longterm outcomes of robot-assisted radical cystectomy for bladder cancer. Eur Urol 2013;64(2):219-24.
56. Snow-Lisy DC, Campbell SC, Gill IS, et al. Robotic and laparoscopic radical cystectomy for bladder cancer: long-term oncologic outcomes. Eur Urol 2014;65(1):193-200.
57. Smith A, Kurpad R, Lal A, et al. Cost analysis of robotic versus open radical cystectomy for bladder cancer. J Urol 2010;183(2):505-9.
58. Martin AD, Nunez RN, Castle EP. Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis. Urology 2011;77(3):621-5.
59. Lee R, Chughtai B, Herman M, et al. Cost-analysis comparison of robot-assisted laparoscopic radical cystectomy (RC) vs open RC. BJU Int 2011;108(6 Pt 2):976-83.
60. Ahmed K, Khan MS, Vats A, et al. Current status of robotic assisted pelvic surgery and future developments. Int J Surg 2009;7(5):431-40.
61. Yu HY, Hevelone ND, Lipsitz SR, et al. Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US nationwide inpatient sample. Eur Urol 2012;61(6): 1239-44.
62. Hardt J, Filipas D, Hohenfellner R, et al. Quality of life in patients with bladder carcinoma after cystectomy: first results of a prospective study. Qual Life Res 2000;9(1):1-12.
63. Kulaksizoglu H, Toktas G, Kulaksizoglu IB, et al. When should quality of life be measured after radical cystectomy? Eur Urol 2002;42(4):350-5.
64. Stegemann A, Rehman S, Brewer K, et al. Short-term patient-reported quality of life after robot-assisted radical cystectomy using the convalescence and recovery evaluation. Urology 2012;79(6):1274-9.
65. Poch MA, Stegemann AP, Rehman S, et al. Short-term patient reported health-related quality of life (HRQL) outcomes after robot-assisted radical cystectomy (RARC). BJU Int 2014;113(2):260-5.
66. Messer JC, Punnen S, Fitzgerald J, et al. Healthrelated quality of life from a prospective randomised clinical trial of robot-assisted laparoscopic vs open radical cystectomy. BJU Int 2014;114(6):896-902.
67. Aboumohamed AA, Raza SJ, Al-Daghmin A, et al. Health-related quality of life outcomes after robotassisted and open radical cystectomy using a validated bladder-specific instrument: a multiinstitutional study. Urology 2014;83(6):1300-8.
68. Smith ND, Castle EP, Gonzalgo ML, et al. The RAZOR trial (randomized open versus robotic cystectomy): study design and trial update. BJU Int 2015;115(2):198-205.
69. Chang SS, Cookson MS, Baumgartner RG, et al. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 2002;167(5):2012-6.
70. Cookson MS, Chang SS, Wells N, et al. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J Urol 2003;169(1):101-4.
71. Hollenbeck BK, Miller DC, Taub D, et al. Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol 2005;174(4 Pt 1):1231-7 [discussion: 1237].
72. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 2009;55(1): 177-85.
73. Svatek RS, Fisher MB, Williams MB, et al. Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy. Urology 2010;76(6):1419-24.
74. Liu SS, Hodgson PS, Carpenter RL, et al. ADL 8-2698, a trans-3, 4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 2001;69(1):66-71.
75. Entereg (alvimopan) prescribing information. Available at: http://www.entereg.com/content/pdf/entereg_prescribing_information.pdf. Accessed October 20, 2014.
76. McNicol ED, Boyce D, Schumann R, et al. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev 2008;(2):CD006332.
77. Wolff BG, Michelassi F, Gerkin TM, et al. Alvimopan, a novel, peripherally acting mu opioid antagonist: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial of major abdominal surgery and postoperative ileus. Ann Surg 2004;240(4):728-34 [discussion: 734-5].
78. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005;48(6): 1114-25.
79. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006;20(1):64-70.
80. Ludwig K, Enker WE, Delaney CP, et al. Gastrointestinal tract recovery in patients undergoing bowel resection: results of a randomized trial of alvimopan and placebo with a standardized accelerated postoperative care pathway. Arch Surg 2008;143(11): 1098-105.
81. Buchler MW, Seiler CM, Monson JR, et al. Clinical trial: alvimopan for the management of postoperative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study. Aliment Pharmacol Ther 2008;28(3):312-25.
82. Cerantola Y, Valerio M, Persson B, et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: enhanced recovery after surgery (ERAS((R))) society recommendations. Clin Nutr 2013;32(6):879-87.
83. Karl A, Buchner A, Becker A, et al. A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study. J Urol 2014;191(2): 335-40.
84. Smith J, Meng ZW, Lockyer R, et al. Evolution of the Southampton enhanced recovery programme for radical cystectomy and the aggregation of marginal gains. BJU Int 2014;114(3):375-83.
85. Dutton TJ, Daugherty MO, Mason RG, et al. Implementation of the Exeter enhanced recovery programme for patients undergoing radical cystectomy. BJU Int 2014;113(5):719-25.
86. Vora A, Marchalik D, Nissim H, et al. Multi-institutional outcomes and cost effectiveness of using alvimopan to lower gastrointestinal morbidity after cystectomy and urinary diversion. Can J Urol 2014; 21(2):7222-7.
87. Lee CT, Chang SS, Kamat AM, et al. Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebocontrolled trial. Eur Urol 2014;66(2):265-72.
88. Kraft M, Maclaren R, Du W, et al. Alvimopan (entereg) for the management of postoperative ileus in patients undergoing bowel resection. P T 2010; 35(1):44-9.
89. Bell TJ, Poston SA, Kraft MD, et al. Economic analysis of alvimopan in north american phase III efficacy trials. Am J Health Syst Pharm 2009;66(15): 1362-8.
90. Poston S, Broder MS, Gibbons MM, et al. Impact of alvimopan (entereg) on hospital costs after bowel resection: results from a large inpatient database. P T 2011;36(4):209-20.
91. Delaney CP, Craver C, Gibbons MM, et al. Evaluation of clinical outcomes with alvimopan in clinical practice: a national matched-cohort study in patients undergoing bowel resection. Ann Surg 2012; 255(4):731-8.
92. Touchette DR, Yang Y, Tiryaki F, et al. Economic analysis of alvimopan for prevention and management of postoperative ileus. Pharmacotherapy 2012;32(2):120-8.
93. Hilton WM, Lotan Y, Parekh DJ, et al. Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis. BJU Int 2013;111(7):1054-60.
94. Kauf TL, Svatek RS, Amiel G, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. J Urol 2014;191(6):1721-7.
95. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29.
96. Lotan Y, Kamat AM, Porter MP, et al. Key concerns about the current state of bladder cancer: a position paper from the bladder cancer think tank, the bladder cancer advocacy network, and the society of urologic oncology. Cancer 2009;115(18): 4096-103.
97. Carter AJ, Nguyen CN. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health 2012;12:526.
98. Noyes K, Singer EA, Messing EM. Healthcare economics of bladder cancer: cost-enhancing and cost-reducing factors. Curr Opin Urol 2008;18(5): 533-9.
99. Zehnder P, Gill IS. Cost-effectiveness of open versus laparoscopic versus robotic-assisted laparoscopic cystectomy and urinary diversion. Curr Opin Urol 2011;21(5):415-9.